Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nemaura Medical Inc. (NMRD)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Devices
Address
57 West 57th Street 10019
New York City, NY, US
New York City, NY, US
CEO
Dewan Fazlul Hoque Chowdhury
Website
nemauramedical.com
IPO
2018-02-05
CIK 1602078 ISIN US6404422080
Description
Nemaura Medical Inc. is a medical technology company dedicated to inventing, developing, and bringing to market diagnostic medical devices. Its flagship product, sugarBEAT, is an innovative, non-invasive continuous glucose monitoring (CGM) system. This device is designed to assist individuals with Type 1 and Type 2 diabetes in managing their condition, and it can also screen for pre-diabetic states. Beyond this, Nemaura offers proBEAT, a wellness guidance service that delivers educational prompts to users about factors influencing their blood sugar profiles. The company also conducts specialized programs aimed at diabetes prevention and reversal. Established in 2009, Nemaura Medical Inc. operates from its headquarters in New York City.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.5K
Beta
0.92
Float Shares
17.26M
Free Float %
42.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +100.00% | +100.00% | +207.69% | +1,900.00% | +0.00% | +19,900.00% | +100.00% | -99.96% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-23.47
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-84.7% Q4'23: -100.0% (vs Q4'22)
-
EPS growth Medical - Devices: +28.5%+3.4% Q4'23: -5.1% (vs Q4'22)
-
FCF margin FCF growth · Medical - Devices: +30.9%-21,024.5%
-
EBIT margin Medical - Devices: +6.2%-10,034.8%
-
ROIC Medical - Devices: +3.3%— Q4'23: -56.2% (vs Q4'22)
-
Share dilution Medical - Devices: 0.0%+6.4% Q4'23: +19.9% (vs Q4'22)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-2.75× Q4'23: -31.61× (vs Q4'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2020 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 700.0K (-100.0%)
|
503.9K
est: 499.3K (+0.9%)
|
77.0K
est: 292.3K (-73.6%)
|
200.0K
est.
|
1.40M
est.
|
3.40M
3.40M – 3.40M
+142.9% YoY
|
| EBITDA |
-4.72M
est: 140.0K (-3,474.1%)
|
-7.34M
est: 99.9K (-7,450.5%)
|
-7.29M
est: 58.5K (-12,563.8%)
|
40.0K
est.
|
280.0K
est.
|
680.0K
680.0K – 680.0K
+142.9% YoY
|
| EBIT |
-4.78M
est: 140.0K (-3,513.2%)
|
-7.57M
est: 99.9K (-7,680.6%)
|
-7.73M
est: 58.5K (-13,323.5%)
|
40.0K
est.
|
280.0K
est.
|
680.0K
680.0K – 680.0K
+142.9% YoY
|
| Net Income |
-4.16M
est: -4.98M (+16.4%)
|
-13.89M
est: -14.35M (+3.2%)
|
-14.14M
est: -14.10M (-0.3%)
|
-7.96M
est.
|
-10.95M
est.
|
-8.58M
-8.58M – -8.58M
+21.6% YoY
|
| SGA |
2.77M
est: 12.31M (-77.5%)
|
6.17M
est: 8.78M (-29.7%)
|
5.60M
est: 5.14M (+8.9%)
|
3.52M
est.
|
24.62M
est.
|
59.80M
59.80M – 59.80M
+142.9% YoY
|
| EPS |
-0.20
est: -0.20 (+0.0%)
|
-0.59
est: -0.58 (-2.3%)
|
-0.57
est: -0.57 (-0.6%)
|
-0.32
est.
|
-0.44
est.
|
-0.35
-0.35 – -0.35
+21.6% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-15.35M
OE per share TTM
-0.57
Owner's Yield
-265,596.34%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
277.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sze Tang Li | 4.69M | 7.00% | 4.69M | — | 4.69M | — | IN | People's Republic of China | 2018-03-02 | ↗ |
| 2 | Alyeska Fund GP, LLC | 2.89M | 9.99% | — | 2.89M | — | — | OO | Delaware | 2024-02-14 | ↗ |
| 3 | Alyeska Investment Group, L.P. | 2.89M | 9.99% | — | 2.89M | — | — | IA | Delaware | 2024-02-14 | ↗ |
| 4 | Anand Parekh | 2.89M | 9.99% | — | 2.89M | — | — | IN | Delaware | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
62.3K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+62,293
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-05 | Ghadar-Ghadr Arash | Officer | P-Purchase | A | Common Stock | 100,000 | 0.14 | 14.0K | 100,000 | — | ↗ |
| 2022-01-31 | Mclarney Justin James | Officer | A-Award | A | Common Stock | 22,293 | 0.00 | — | 22,293 | — | ↗ |
| 2022-01-28 | Timol Bashir | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 8,000 | 3.98 | 31.8K | 8,000 | — | ↗ |
| 2022-01-28 | Natha Salim | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 3.98 | 31.8K | 8,000 | — | ↗ |
| 2022-01-28 | Moore Thomas Peter | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 3.98 | 31.8K | 8,000 | — | ↗ |
| 2022-01-28 | Johnson Timothy Christopher | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 3.98 | 31.8K | 8,000 | — | ↗ |
| 2022-01-28 | Chowdhury Dewan Fazlul Hoque | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 8,000 | 3.98 | 31.8K | 8,000 | — | ↗ |
| 2022-01-05 | Ghadar-Ghadr Arash | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-09-15 | Mclarney Justin James | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-06-05 | Timol Bashir | Director / Officer | J-Other | A | Common Stock | 27,082,000 | 0.00 | — | 27,082,100 | — | ↗ |
| 2018-06-05 | Ismail Sufyan | 10% Owner | J-Other | A | Common Stock | 22,705,000 | 0.00 | — | 22,705,250 | — | ↗ |
| 2018-06-05 | Chowdhury Dewan Fazlul Hoque | Director / Officer / 10% Owner | C-Conversion | D | Series A Convertible Preferred Stock | 88 | 0.00 | — | 0 | — | ↗ |
| 2017-11-06 | Timol Bashir | Director / Officer | J-Other | A | Series A Convertible Preferred Stock | 27,082 | 0.00 | — | 27,082 | — | ↗ |
| 2017-11-06 | Ismail Sufyan | 10% Owner | J-Other | A | Series A Convertible Preferred Stock | 22,705 | 0.00 | — | 22,705 | — | ↗ |
| 2017-11-06 | Chowdhury Dewan Fazlul Hoque | Director / Officer / 10% Owner | J-Other | A | Series A Convertible Preferred Stock | 87,537 | 0.00 | — | 87,537 | — | ↗ |
| 2017-08-03 | Moore Thomas Peter | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-26 | Natha Salim | Director | — | D | Common Stock | 0 | 0.00 | — | 4,006,389 | — | ↗ |
| 2017-07-17 | Johnson Timothy Christopher | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-01-12 | Anderson Iain | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-12-05 | Farrar Kathryn | Director / Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 3,000 | — | ↗ |
| 2014-08-12 | Toon Richard | Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 3,000 | — | ↗ |
| 2014-08-12 | Timol Bashir | Director / 10% Owner | — | D | COMMON STOCK | 0 | 0.00 | — | 26,261,100 | — | ↗ |
| 2014-08-12 | Pomeroy Julie | Director / Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 3,000 | — | ↗ |
| 2014-08-12 | Ismail Sufyan | 10% Owner | — | D | COMMON STOCK | 0 | 0.00 | — | 21,884,250 | — | ↗ |
| 2014-08-12 | Chowdhury Dewan Fazlul Hoque | Director / Officer / 10% Owner | — | D | COMMON STOCK | 0 | 0.00 | — | 87,537,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-2.1K
Shares Outstanding
40.35M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2018 | Dewan Fazlul Hoque Chowdhury (Principal Executive Officer) | 106.4K | — | — | — | — | 390.00 | 106.8K | 0.00% | ↗ |
| 2 | 2018 | Iain Anderson (Principal Financial Officer) | 57.9K | — | — | — | — | 297.00 | 58.2K | 0.00% | ↗ |
| 3 | 2017 | Dewan Fazlul Hoque Chowdhury (Principal Executive Officer) | 105.2K | — | — | — | — | — | 105.2K | 0.00% | ↗ |
| 4 | 2017 | Iain Anderson (Principal Financial Officer) | 34.8K | — | — | — | — | — | 34.8K | 0.00% | ↗ |
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dewan Fazlul Hoque Chowdhury | Chairman, Interim Chief Financial Officer, Chief Executive Officer, President and Principal Financial & Accounting Officer | 338.6K | — |
| Arash Ghadar | Chief Operating Officer | — | — |
| Jay L. Warner | Head of U.S. Commercial Operations | — | male |
| Samantha Sanders | Global Head of Digital Programs | — | female |
| Thomas Bendix Mortensen | Head of E.U. Commercial Operations & Marketing | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2022-01-10 | 2022-02-15 | Dianne Feinstein | CA | Spouse | Sale | $15,001 - $50,000 | ↗ |
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NMRD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
